Maxim raised the firm’s price target on Rezolute to $10 from $8. Rezolute announced IND clearance for a Phase 3 registrational study ersodetug for the treatment of hypoglycemia due to tumor hyperinsulinism, the analyst tells investors in a research note. With two Phase 3 trials for the ersodetug program, the oral kallikrein inhibitor RZ402 looking for a partnership following the successful Phase 2 study, and a strong balance sheet to provide runway through multiple milestones, the firm reiterates its Buy rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute Receives FDA Nod for Hypoglycemia Drug RZ358
- Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
- Rezolute announces FDA clearance of IND application for Phase 3 study of RZ358
- Rezolute to Participate in the BTIG Virtual Biotechnology Conference
- Five Below, Qualcomm downgraded: Wall Street’s top analyst calls